Cefepime‐Zidebactam: Leveraging β‐Lactam Enhancement Against Difficult‐to‐Treat and Metallo‐β‐Lactamase‐Producing Gram‐Negative Pathogens
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-11 · 46 (11)
DOI: 10.1002/phar.70208 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 12.10.2026. Verfasst von Sean R Van Helden und 5 weiteren Autor:innen. Beteiligte Einrichtung: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University…. Hauptthemen laut MEDLINE: Gram-Negative Bacteria, Azabicyclo Compounds, Anti-Bacterial Agents, Gram-Negative Bacterial Infections. Die Arbeit nennt 130 Literaturangaben.
Abstract (Originalsprache)
Carbapenem resistance among Gram‐negative bacteria remains a serious public health threat, with metallo‐β‐lactamase (MBL)‐producing organisms increasing substantially in prevalence and few therapeutic options available to adequately address these difficult‐to‐treat pathogens. Cefepime‐zidebactam (FEP‐ZID) is a novel β‐lactam/β‐lactam enhancer combination that offers a mechanistically distinct approach to overcoming resistance in Gram‐negative organisms. Zidebactam contributes three complementary mechanisms: inhibition of Class A and C β‐lactamases, direct antibacterial activity via PBP2 inhibition, and enhancement of cefepime activity through a reduction in the pharmacodynamic exposure required for bactericidal effect, allowing FEP‐ZID to achieve substantial reductions in bacterial burden even in isolates with elevated minimum inhibitory concentrations (MICs). FEP‐ZID was recently approved in the United States for the treatment of complicated urinary tract infection (cUTI), including acute pyelonephritis, caused by Enterobacterales and/or Pseudomonas aeruginosa . FEP‐ZID demonstrates broad in vitro and in vivo activity against isolates producing Class A, B, C, and D β‐lactamases, as well as organisms harboring PBP3 alterations that are otherwise associated with reduced susceptibility to currently available MBL‐active therapies. This spectrum extends across carbapenem‐resistant Enterobacterales, P. aeruginosa , and Acinetobacter baumannii , and includes activity against isolates with porin loss and efflux upregulation, resistance mechanisms that commonly limit the utility of other β‐lactam‐based agents. In vivo infection models utilizing humanized regimens have demonstrated bactericidal activity against isolates with FEP‐ZID MICs up to 64 μg/mL. The Phase 3 ENHANCE I trial demonstrated noninferiority and subsequent superiority over meropenem in cUTI (including acute pyelonephritis), driven primarily by microbiological response, with favorable outcomes observed across many baseline pathogens, including extended‐spectrum β‐lactamase‐producing isolates and patients with concomitant bacteremia. Compassionate use experience further suggests possible utility in severe multidrug‐resistant infections across multiple infection types, including bloodstream, osteoarticular, and intra‐abdominal infections caused by MBL‐producing organisms. Collectively, available preclinical and clinical evidence positions FEP‐ZID as a mechanistically distinct option for difficult‐to‐treat Gram‐negative infections, with additional clinical study needed to define its role beyond the currently approved indication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
- University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.
- University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA.
- Department of Pharmacy Services, Detroit Receiving Hospital, Detroit Medical Center, Detroit, Michigan, USA.
- Division of Infectious Diseases, School of Medicine, Wayne State University, Detroit, Michigan, USA.
ORCID-Profile: Sean R Van Helden, Adesanya A Akinleye, Ashlan J Kunz Coyne, Amer El Ghali, Niharika Thota, Michael J Rybak
Zitieren
APA
Van Helden, S. R., Akinleye, A. A., Kunz Coyne, A. J., El Ghali, A., Thota, N., & Rybak, M. J. (2026). Cefepime‐Zidebactam: Leveraging β‐Lactam Enhancement Against Difficult‐to‐Treat and Metallo‐β‐Lactamase‐Producing Gram‐Negative Pathogens. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(11). https://doi.org/10.1002/phar.70208
Vancouver
Van Helden SR, Akinleye AA, Kunz Coyne AJ, El Ghali A, Thota N, Rybak MJ. Cefepime‐Zidebactam: Leveraging β‐Lactam Enhancement Against Difficult‐to‐Treat and Metallo‐β‐Lactamase‐Producing Gram‐Negative Pathogens. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(11). doi:10.1002/phar.70208
BibTeX
@article{VanHelden2026,
author = {Van Helden, Sean R and Akinleye, Adesanya A and Kunz Coyne, Ashlan J and El Ghali, Amer and Thota, Niharika and Rybak, Michael J},
title = {Cefepime‐Zidebactam: Leveraging β‐Lactam Enhancement Against Difficult‐to‐Treat and Metallo‐β‐Lactamase‐Producing Gram‐Negative Pathogens},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2026},
volume = {46},
number = {11},
doi = {10.1002/phar.70208}
}
EUVIMED